Department of Gynecologic Surgery, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France; Laboratoire d'ImmunoRhumatologie Moléculaire, Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Transplantex NG, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Department of Gynecologic and Breast Oncological Surgery, Georges-Pompidou European Hospital, APHP. Centre, France.
J Gynecol Obstet Hum Reprod. 2022 Feb;51(2):102283. doi: 10.1016/j.jogoh.2021.102283. Epub 2021 Dec 5.
Epithelial ovarian cancer (EOC) is the most lethal of all gynecological cancers. Despite excellent responses to standard treatment in approximately 70% of patients, most of them will relapse within 5 years of initial treatment and many of them will develop chemotherapy-resistant disease. It is then important to find other means of treatment for these patients such as immunotherapy or targeted therapy. To understand immunotherapy, it is important to explain the dynamic interplay between cancer and the immune system. Compared to traditional tumor therapies, immunotherapy acts primarily on the immune system or the tumor microenvironment but not directly on the tumor cells, and it may also promote synergistic anti-tumor actions as part of a combined treatment. The aim of this narrative review is to provide a basic understanding of immunotherapy the interest of this treatment in EOC, and to present the main ongoing studies that could change patient management in the future.
上皮性卵巢癌 (EOC) 是所有妇科癌症中最致命的一种。尽管约 70%的患者对标准治疗有极好的反应，但其中大多数在初始治疗后 5 年内会复发，而且许多患者会发展出对化疗耐药的疾病。因此，对于这些患者来说，找到其他治疗方法很重要，如免疫疗法或靶向治疗。为了理解免疫疗法，重要的是要解释癌症和免疫系统之间的动态相互作用。与传统的肿瘤治疗方法相比，免疫疗法主要作用于免疫系统或肿瘤微环境，而不是直接作用于肿瘤细胞，并且它还可能作为联合治疗的一部分促进协同抗肿瘤作用。本综述的目的是提供对免疫疗法的基本了解，探讨这种治疗方法在上皮性卵巢癌中的应用，并介绍未来可能改变患者管理的主要正在进行的研究。
